[11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics [2]

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7522-

  Gustafson, Daniel L ^a,b   Eckhardt, S Gail ^b,c   Bradshaw Pierce, Erica L ^c  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Cancer Center   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOCETAXEL;

ACCURACY; LETTER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MODEL; MONTE CARLO METHOD; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 37549009129     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1946     Document Type: Letter

References (4)

1. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 2007;13:2768-76.
2. Gustafson DL. Use of physiologically-based pharmacokinetic modeling coupled to Monte Carlo simulation to predict the pharmacokinetic interactions between doxorubicin and taxanes in human populations. Proc Am Assoc Cancer Res 2002;43:208.
3. Thomas RS, Lytle WE, Keefe TJ, Constan AA, Yang RSH. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method. Fund Appl Toxicol 1996;31:19-28.
4. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000;17:1551-7.